Sandbox gc: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' [[ | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' For patients at risk of developing HF, natriuretic peptide biomarker–based screening followed by team- based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset HF ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' <nowiki>"</nowiki> | ||
|} | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit) | |||
|- | |||
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Routine combined use of an [[ACEIs|ACE inhibitor]], [[Angiotensin II receptor blockers|ARB]], and [[aldosterone antagonist]] is not recommended for patients with current or prior symptoms of [[heart failure]] and reduced [[left ventricular ejection fraction]] ([[LVEF]]). ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightCoral; ; width: 300px"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) | |||
|- | |||
| bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|ARNI]] should not be administered concomitantly with [[ACE inhibitor|ACE inhibitors]] or within 36 hours of the last dose of an ACE inhibitor. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-R]])'' <nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightCoral"|<nowiki>"</nowiki>'''2.''' [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|ARNI]] should not be administered to patients with a history of [[angioedema]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-EO]])'' <nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Angiotensin II receptor blockers]] are reasonable to use as alternatives to [[ACEIs|ACE inhibitors]] as first-line therapy for patients with mild to moderate [[heart failure]] and reduced [[left ventricular ejection fraction]] ([[LVEF]]), especially for patients already taking [[Angiotensin II receptor blockers|ARBs]] for other indications.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | |||
|} | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[Angiotensin II receptor blockers]] are reasonable to use as alternatives to [[ACEIs|ACE inhibitors]] as first-line therapy for patients with mild to moderate [[heart failure]] and reduced [[left ventricular ejection fraction]] ([[LVEF]]), especially for patients already taking [[Angiotensin II receptor blockers|ARBs]] for other indications.''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])'' <nowiki>"</nowiki> | |||
|} | |} | ||
Revision as of 17:13, 16 October 2017
| Class I |
| "1. For patients at risk of developing HF, natriuretic peptide biomarker–based screening followed by team- based care, including a cardiovascular specialist optimizing GDMT, can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new-onset HF (Level of Evidence: B-R) " |
| Class III (No Benefit) |
| "1. Routine combined use of an ACE inhibitor, ARB, and aldosterone antagonist is not recommended for patients with current or prior symptoms of heart failure and reduced left ventricular ejection fraction (LVEF). (Level of Evidence: C) " |
| Class III (Harm) |
| "1. ARNI should not be administered concomitantly with ACE inhibitors or within 36 hours of the last dose of an ACE inhibitor. (Level of Evidence: B-R) " |
| "2. ARNI should not be administered to patients with a history of angioedema. (Level of Evidence: C-EO) " |
| Class IIa |
| "1. Angiotensin II receptor blockers are reasonable to use as alternatives to ACE inhibitors as first-line therapy for patients with mild to moderate heart failure and reduced left ventricular ejection fraction (LVEF), especially for patients already taking ARBs for other indications.(Level of Evidence: A) " |
| Class IIb |
| "1. Angiotensin II receptor blockers are reasonable to use as alternatives to ACE inhibitors as first-line therapy for patients with mild to moderate heart failure and reduced left ventricular ejection fraction (LVEF), especially for patients already taking ARBs for other indications.(Level of Evidence: A) " |